US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5811310A
(en)
|
1986-09-30 |
1998-09-22 |
Albert Einstein College Of Medicine Of Yeshiva Univ. |
The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US5231000A
(en)
|
1987-10-08 |
1993-07-27 |
The Mclean Hospital |
Antibodies to A4 amyloid peptide
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5283187A
(en)
|
1987-11-17 |
1994-02-01 |
Brown University Research Foundation |
Cell culture-containing tubular capsule produced by co-extrusion
|
US4892538A
(en)
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
WO1989008114A1
(en)
|
1988-02-25 |
1989-09-08 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
US5506126A
(en)
|
1988-02-25 |
1996-04-09 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
RU2138512C1
(ru)
|
1989-03-21 |
1999-09-27 |
Дзе Иммюн Риспонз Корпорейшн |
Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
|
ES2112838T5
(es)
|
1989-07-19 |
2004-09-01 |
Connetics Corporation |
Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
WO1993010819A1
(en)
*
|
1991-11-26 |
1993-06-10 |
Alkermes, Inc. |
Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
NZ236819A
(en)
|
1990-02-03 |
1993-07-27 |
Max Planck Gesellschaft |
Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
JP2780507B2
(ja)
|
1991-03-29 |
1998-07-30 |
松下電器産業株式会社 |
内燃機関用フィルタ再生装置
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
AU4528493A
(en)
|
1992-06-04 |
1994-01-04 |
Regents Of The University Of California, The |
In vivo gene therapy with intron-free sequence of interest
|
ATE191853T1
(de)
|
1992-07-27 |
2000-05-15 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5955317A
(en)
|
1993-01-25 |
1999-09-21 |
Takeda Chemical Industries, Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
DE69432629T3
(de)
|
1993-01-25 |
2008-01-17 |
Takeda Pharmaceutical Co. Ltd. |
Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
US5417972A
(en)
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
US5443953A
(en)
|
1993-12-08 |
1995-08-22 |
Immunomedics, Inc. |
Preparation and use of immunoconjugates
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5688651A
(en)
|
1994-12-16 |
1997-11-18 |
Ramot University Authority For Applied Research And Development Ltd. |
Prevention of protein aggregation
|
US5586553A
(en)
|
1995-02-16 |
1996-12-24 |
Minimed Inc. |
Transcutaneous sensor insertion set
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US6015555A
(en)
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
WO1996039628A1
(en)
|
1995-06-06 |
1996-12-12 |
Stemcell Therapeutics L.L.C. |
GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
DE19528388A1
(de)
|
1995-08-02 |
1997-02-06 |
Hans Peter Prof Dr Med Zenner |
Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
|
WO1997008320A1
(en)
|
1995-08-18 |
1997-03-06 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
DE69810481T2
(de)
|
1997-06-13 |
2003-09-25 |
Genentech Inc |
Stabilisierte antikörperformulierung
|
CA2293829C
(en)
|
1997-06-24 |
2011-06-14 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
WO1999002567A2
(en)
|
1997-07-08 |
1999-01-21 |
Board Of Regents, The University Of Texas System |
Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
MY136203A
(en)
|
1998-08-11 |
2008-08-29 |
Idec Pharma Corp |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
PL200586B1
(pl)
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
CA2350064C
(en)
|
1998-11-09 |
2012-05-08 |
Idec Pharmaceuticals Corporation |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
|
EP1616572B1
(en)
|
1998-11-09 |
2010-09-01 |
Biogen Idec Inc. |
Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
EP1035172A3
(en)
|
1999-03-12 |
2002-11-27 |
Fuji Photo Film Co., Ltd. |
Azomethine compound and oily magenta ink
|
PT1914244E
(pt)
|
1999-04-09 |
2013-07-26 |
Kyowa Hakko Kirin Co Ltd |
Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
|
IL129427A0
(en)
|
1999-04-13 |
2000-02-17 |
Yeda Res & Dev |
Preparation of biologically active molecules
|
SE9901428D0
(sv)
|
1999-04-21 |
1999-04-21 |
Karolinska Innovations Ab |
Amphibodies
|
PL200134B1
(pl)
|
1999-05-07 |
2008-12-31 |
Genentech Inc |
Zastosowanie przeciwciała anty-CD20
|
ES2331644T3
(es)
|
1999-06-09 |
2010-01-12 |
Immunomedics, Inc. |
Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
WO2000077178A1
(en)
|
1999-06-16 |
2000-12-21 |
Boston Biomedical Research Institute |
IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
|
DE19930748C2
(de)
|
1999-07-02 |
2001-05-17 |
Infineon Technologies Ag |
Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
|
WO2001003734A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
JP2003513012A
(ja)
|
1999-08-11 |
2003-04-08 |
アイデック ファーマスーティカルズ コーポレイション |
抗cd20抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
|
US6451284B1
(en)
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
WO2001025454A2
(en)
|
1999-10-04 |
2001-04-12 |
Medicago Inc. |
Method for regulating transcription of foreign genes in the presence of nitrogen
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
MXPA02004599A
(es)
|
1999-11-08 |
2002-10-23 |
Idec Pharma Corp |
Tratamiento de tumores malignos de celula b utilizando anticuerpos anti-cd40l en combinacion con anticuerpos anti-cd20 y/o agentes quimioterapeuticos y radioterapia.
|
US20020006404A1
(en)
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
KR20080059676A
(ko)
|
1999-11-29 |
2008-06-30 |
뉴로겜 인터내셔널 리미티드 |
알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용백신
|
US20020094335A1
(en)
|
1999-11-29 |
2002-07-18 |
Robert Chalifour |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
WO2001049698A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
US20020127652A1
(en)
|
2000-02-11 |
2002-09-12 |
Schambye Hans Thalsgard |
Follicle stimulating hormones
|
EP1125905A1
(en)
|
2000-02-16 |
2001-08-22 |
Pepscan Systems B.V. |
Segment synthesis
|
US20030185796A1
(en)
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
WO2001072333A1
(en)
|
2000-03-24 |
2001-10-04 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2
|
KR20020091170A
(ko)
|
2000-03-31 |
2002-12-05 |
아이덱 파마슈티칼즈 코포레이션 |
B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용
|
NZ521540A
(en)
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
AU5914201A
(en)
|
2000-04-25 |
2001-11-07 |
Idec Pharma Corp |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
CA2412882A1
(en)
|
2000-06-30 |
2002-01-10 |
Maxygen Aps |
Peptide extended glycosylated polypeptides
|
KR20030031957A
(ko)
|
2000-07-12 |
2003-04-23 |
아이덱 파마슈티칼즈 코포레이션 |
B 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 b 세포 악성종양의 치료
|
US20030148404A1
(en)
|
2000-07-27 |
2003-08-07 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
|
CA2313828A1
(en)
|
2000-08-01 |
2002-02-01 |
Institut De Recherches Cliniques De Montreal/Ircm |
Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
|
KR20040023565A
(ko)
|
2000-09-18 |
2004-03-18 |
아이덱 파마슈티칼즈 코포레이션 |
B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CA2785941C
(en)
|
2000-10-06 |
2017-01-10 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US20020128448A1
(en)
|
2000-10-20 |
2002-09-12 |
Idec Pharmaceuticals Corporation |
Variant IgG3 Rituxan and therapeutic use thereof
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
ATE378403T1
(de)
|
2000-11-30 |
2007-11-15 |
Medarex Inc |
Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
ATE385811T1
(de)
|
2000-12-19 |
2008-03-15 |
Palatin Technologies Inc |
Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen
|
IL156618A0
(en)
|
2000-12-28 |
2004-01-04 |
Altus Biologics Inc |
Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
|
CA2436092A1
(en)
|
2001-01-29 |
2002-08-08 |
Idec Pharmaceutical Corporation |
Modified antibodies and methods of use
|
WO2002096948A2
(en)
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
WO2002079255A1
(en)
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceuticals Corporation |
RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
|
AU2002257162A1
(en)
|
2001-04-30 |
2002-11-11 |
Eli Lilly And Company |
Humanized antibodies
|
DE60230736D1
(de)
|
2001-04-30 |
2009-02-26 |
Lilly Co Eli |
HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
WO2003061694A1
(en)
|
2001-05-10 |
2003-07-31 |
Seattle Genetics, Inc. |
Immunosuppression of the humoral immune response by anti-cd20 antibodies
|
AU2002315168A1
(en)
|
2001-06-14 |
2003-01-02 |
Intermune, Inc. |
Combination therapy of gamma-interferon and b cell specific antibodies
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
JP4317010B2
(ja)
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ,インコーポレイティド |
IgG抗体の安定な凍結乾燥医薬製剤
|
CN1555411A
(zh)
|
2001-08-03 |
2004-12-15 |
���迨�����\���ɷݹ�˾ |
抗体-依赖性细胞毒性增大的抗体糖基化变体
|
DK1944040T3
(da)
|
2001-08-17 |
2012-10-29 |
Univ Washington |
Analysefremgangsmåde for Alzheimers sygdom
|
WO2003016466A2
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
EP2131198B1
(en)
|
2001-09-20 |
2013-03-27 |
Board of Regents, The University of Texas System |
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CA2469045A1
(en)
|
2001-12-07 |
2003-06-19 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
WO2003068821A2
(en)
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
JP4628679B2
(ja)
|
2002-04-09 |
2011-02-09 |
協和発酵キリン株式会社 |
Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
JPWO2003085107A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
ゲノムが改変された細胞
|
US20030219818A1
(en)
|
2002-05-10 |
2003-11-27 |
Bohen Sean P. |
Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
AR040778A1
(es)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
US20040146512A1
(en)
|
2002-10-09 |
2004-07-29 |
Arnon Rosenthal |
Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
EP2330130B1
(en)
|
2002-10-17 |
2014-08-27 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
KR101186210B1
(ko)
|
2002-12-03 |
2012-10-08 |
블랜체트 록펠러 뉴로사이언시즈 인스티튜트 |
혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
|
EP1572744B1
(en)
|
2002-12-16 |
2010-06-09 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
RU2332986C2
(ru)
|
2003-04-04 |
2008-09-10 |
Дженентек, Инк. |
Высококонцентрированные композиции антител и белков
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
CA2548787A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition specifically binding to ganglioside gm2
|
RS55723B1
(sr)
|
2003-11-05 |
2017-07-31 |
Roche Glycart Ag |
Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
BR122018071968B8
(pt)
|
2003-11-06 |
2021-07-27 |
Seattle Genetics Inc |
conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
|
US20050142133A1
(en)
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
EP1697741A4
(en)
|
2003-12-04 |
2008-02-13 |
Xencor Inc |
PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
GB0412186D0
(en)
|
2004-05-28 |
2004-06-30 |
Univ Cambridge Tech |
Production of recombinant protein
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7697967B2
(en)
|
2005-12-28 |
2010-04-13 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing analyte sensor insertion
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
AR052469A1
(es)
|
2005-01-28 |
2007-03-21 |
Wyeth Corp |
Formulaciones liquidas estabilizadas de polipeptido
|
NZ563580A
(en)
|
2005-06-07 |
2010-09-30 |
Esbatech An Alcon Biomedical R |
Stable and soluble antibodies inhibiting TNFaplha
|
US8142781B2
(en)
|
2005-10-07 |
2012-03-27 |
Armagen Technologies, Inc. |
Fusion proteins for blood-brain barrier delivery
|
DE102005059242A1
(de)
|
2005-12-12 |
2007-06-14 |
Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten |
Molekulare Marker für eine Tumordiagnose und -therapie
|
PE20100684A1
(es)
|
2005-12-12 |
2010-10-04 |
Hoffmann La Roche |
Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
|
DE102006013531A1
(de)
|
2006-03-24 |
2007-09-27 |
Lts Lohmann Therapie-Systeme Ag |
Polylactid-Nanopartikel
|
KR20080104160A
(ko)
|
2006-03-28 |
2008-12-01 |
에프. 호프만-라 로슈 아게 |
항-igf-1r 인간 단일클론 항체 제형
|
CA2656558A1
(en)
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
CA2661042C
(en)
|
2006-08-18 |
2012-12-11 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
AU2007291501B2
(en)
|
2006-08-31 |
2012-07-12 |
F. Hoffmann-La Roche Ag |
Method for the production of insulin-like growth factor-I
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
CA2671968A1
(en)
|
2006-12-11 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Abeta antibody parenteral formulation
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
AU2008248780B2
(en)
|
2007-05-02 |
2013-01-31 |
F. Hoffmann-La Roche Ag |
Method for stabilizing a protein
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
DK2178916T3
(da)
|
2007-07-31 |
2015-01-12 |
Regeneron Pharma |
Humane antistoffer mod human cd20 og fremgangsmåde til anvendelse deraf
|
US20090162359A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
CA2716738A1
(en)
|
2008-04-07 |
2009-10-15 |
Zymogenetics, Inc. |
Thrombin activator compositions and methods of making and using the same
|
WO2010011695A1
(en)
|
2008-07-21 |
2010-01-28 |
Arstasis, Inc. |
Devices, methods, and kits for forming tracts in tissue
|
US20100077498A1
(en)
|
2008-09-11 |
2010-03-25 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery in the mouse
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
WO2010034441A1
(en)
|
2008-09-26 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
Bispecific anti-egfr/anti-igf-1r antibodies
|
US20130090457A1
(en)
|
2008-10-31 |
2013-04-11 |
Janssen Biotech, Inc. |
Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
JP5501439B2
(ja)
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
MX2011010158A
(es)
|
2009-04-07 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-2/anti-c-met.
|
WO2011066374A2
(en)
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
FR2953841B1
(fr)
*
|
2009-12-16 |
2011-12-30 |
Centre Nat Rech Scient |
Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
|
WO2011116387A1
(en)
|
2010-03-19 |
2011-09-22 |
Tetragenetics, Inc. |
Production of aglycosylated monoclonal antibodies in ciliates
|
RU2439160C1
(ru)
*
|
2010-06-25 |
2012-01-10 |
Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) |
Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
KR102099462B1
(ko)
|
2010-11-30 |
2020-04-10 |
제넨테크, 인크. |
저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
|
JP6190723B2
(ja)
|
2010-12-01 |
2017-08-30 |
アルダーバイオ ホールディングス エルエルシー |
抗ngf組成物およびその使用
|
WO2012087835A2
(en)
|
2010-12-22 |
2012-06-28 |
Boston Biomedical Research Institute |
Compositions and methods for enhancing protein folding
|
MA34820B1
(fr)
*
|
2011-01-06 |
2014-01-02 |
Glaxo Group Ltd |
Ligandise se liant au récepteur ii du tgf-bêta
|
US20130315901A1
(en)
|
2011-01-10 |
2013-11-28 |
Glaxo Group Limited |
Novel uses
|
EP2681245B1
(en)
|
2011-03-03 |
2018-05-09 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
US9598496B2
(en)
|
2011-05-09 |
2017-03-21 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
CN102957288B
(zh)
|
2011-08-10 |
2017-12-12 |
德昌电机(深圳)有限公司 |
驱动装置及其有刷电机
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
US20130058937A1
(en)
|
2011-08-23 |
2013-03-07 |
Johannes Auer |
Bispecific antigen binding molecules
|
HUE038225T2
(hu)
|
2011-08-23 |
2018-10-29 |
Roche Glycart Ag |
Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
|
WO2013039471A1
(en)
|
2011-09-12 |
2013-03-21 |
Janssen Biotech Inc. |
Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
LT2785375T
(lt)
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
US10633451B2
(en)
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
US20150044718A1
(en)
|
2012-02-29 |
2015-02-12 |
Hoffmann-La Roche Inc. |
On-column enzymatic cleavage
|
RU2014140137A
(ru)
|
2012-03-08 |
2016-04-27 |
Ф.Хоффманн-Ля Рош Аг |
Лекарственный препарат антитела к бета-амилоиду
|
BR112014024903A2
(pt)
|
2012-04-05 |
2017-07-11 |
Hoffmann La Roche |
anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
|
JP6419068B2
(ja)
*
|
2012-05-21 |
2018-11-07 |
ジェネンテック, インコーポレイテッド |
血液脳関門輸送の安全性を改善するための方法
|
EP2668901A1
(en)
|
2012-05-31 |
2013-12-04 |
Roche Diagniostics GmbH |
Sensor insertion assembly, sensor cartridge, and inserter
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
RS58928B1
(sr)
|
2012-08-29 |
2019-08-30 |
Hoffmann La Roche |
Transporter za krvno-moždanu barijeru
|
JP6408993B2
(ja)
|
2012-09-07 |
2018-10-17 |
ジェネンテック, インコーポレイテッド |
タイプII抗CD20抗体と選択的Bcl−2インヒビターの併用療法
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CA2887933A1
(en)
|
2012-10-12 |
2014-04-17 |
Arizona Board Of Agents, On Behalf Of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
KR102264570B1
(ko)
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
JP2016501881A
(ja)
|
2012-12-04 |
2016-01-21 |
アッヴィ・インコーポレイテッド |
血液脳関門(bbb)を透過する二重特異性結合タンパク質
|
EP3444278A1
(en)
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
WO2014153114A1
(en)
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
WO2014153195A1
(en)
|
2013-03-14 |
2014-09-25 |
Bayer Healthcare Llc |
Monoclonal antibodies against antithrombin beta complexed with heparin
|
US9732150B2
(en)
|
2013-03-14 |
2017-08-15 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
DE102013208865A1
(de)
|
2013-05-14 |
2014-11-20 |
Beiersdorf Ag |
Stabilisierte Zubereitungen mit einem Gehalt an Ascorbinsäure und Phosphationen
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
KR20160037173A
(ko)
|
2013-08-02 |
2016-04-05 |
에프. 호프만-라 로슈 아게 |
치료학적 융합 단백질
|
WO2015052230A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
EP3176185A1
(en)
|
2013-11-04 |
2017-06-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
MX2016005801A
(es)
|
2013-11-07 |
2016-11-29 |
Ono Pharmaceutical Co |
Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.
|
CN111499743B
(zh)
|
2013-11-21 |
2024-01-12 |
豪夫迈·罗氏有限公司 |
抗-α-突触核蛋白抗体及使用方法
|
PL3192812T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
CA2929149A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Improved recombinant polypeptide production methods
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
WO2016020309A1
(en)
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
WO2016160032A1
(en)
|
2015-04-03 |
2016-10-06 |
Entropic Communications, Inc. |
Low power adc with pulsed bias
|
US20160297581A1
(en)
|
2015-04-13 |
2016-10-13 |
Aplix Inc |
Closable container
|
HRP20220304T1
(hr)
|
2015-06-24 |
2022-05-13 |
F. Hoffmann - La Roche Ag |
Anti-transferinska receptorska protutijela s prilagođenim afinitetom
|
CN114409783A
(zh)
|
2015-06-24 |
2022-04-29 |
Jcr制药股份有限公司 |
通过血脑屏障的抗人转铁蛋白受体抗体
|
WO2016207091A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
PE20181004A1
(es)
|
2015-10-02 |
2018-06-26 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP2017187722A
(ja)
|
2016-04-08 |
2017-10-12 |
株式会社リコー |
画像濃度検出装置及び画像形成装置
|